Infection control specialist Tristel has reported revenue growth of 10.9% to £5.1m for the six months to 31 December 2011, driven by overseas sales.
Sales in China and Germany and a launch into the Australian hospital market pushed overseas sales up by more than 100% to £775,000.
“All these new activities are still in their infancy and we can expect substantial contributions from them in the future,” said Tristel’s chief executive Paul Swinney.
Pre-tax profit fell to £262,000 from £433,000.
Swinney added: “We have now levelled off our investment in people and overheads and as we continue to grow sales in the areas we invested in last year we will see a significant improvement in profitability.”
Tristel is now fully engaged in the manufacture and sale of disinfectants and cleaning products in three markets: hospital infection control; animal healthcare (mainly veterinary practices) and manufacturers of pharmaceutical and personal care products for contamination control in their manufacturing processes.